Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer

Oncology Research

Volumn 20, Issue 4, 2012, Pages 179-185

  Kawakami, Kazuyoshi ^a,b   Tunoda, Takashi ^a   Takiguchi, Tomomi ^a   Shibata, Keiko ^b   Ohtani, Takayuki ^c   Kizu, Junko ^c   Nishio, Makoto ^a   Horai, Takeshi ^a   Hama, Toshihiro ^a   Taguchi, Kyoji ^b  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Cox proportional hazard analysis; Creatinine clearance; Non small cell lung cancer; Pack year; Peripheral neuropathy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; C REACTIVE PROTEIN; CALCIUM; CARBOPLATIN; CHLORIDE; CREATININE; DEXAMETHASONE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PACLITAXEL; POTASSIUM; SODIUM; UREA;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY MASS; BODY SURFACE; BONE MARROW SUPPRESSION; BONE METASTASIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHLORIDE BLOOD LEVEL; CLINICAL ARTICLE; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; FEMALE; GENDER; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; MALAISE; MALE; NEUTROPHIL COUNT; PERIPHERAL NEUROPATHY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; SODIUM BLOOD LEVEL; THROMBOCYTE COUNT; TREATMENT WITHDRAWAL; UREA NITROGEN BLOOD LEVEL;

EID: 84871882087     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504012X13522227232192     Document Type: Article

References (24)

1. Rapp, E.; Pater, J. L.; Willan, A.; Cormier, Y.; Murray, N.; Evans, W. K.; Hodson, D. I.; Clark, D. A.; Feld, R. F.; Arnold, A. M.; Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J. Clin. Oncol. 6:633-641; 1988.
2. Ohe, Y.; Ohashi, Y.; Kubota, K.; Tamura, T.; Nakagawa, K.; Negoro, S.; Nishiwaki, Y.; Saijo, N.; Ariyoshi, Y.; Fukuoka, M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann. Oncol. 18:317-323; 2007.
3. Sandler, A.; Gray, R.; Perry, M. C.; Brahmer, J.; Schiller, J. H.; Dowlati, A.; Lilenbaum, R.; Johnson, D. H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355:2542-2550; 2006.
4. Georgoulias, V.; Ardavanis, A.; Agelidou, A.; Agelidou, M.; Chandrinos, V.; Tsaroucha, E.; Toumbis, M.; Kouroussis, C.; Syrigos, K.; Polyzos, A.; Samaras, N.; Papakotoulas, P.; Christofilakis, C.; Ziras, N.; Alegakis, A. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: A randomized, multicenter phase III trial. J. Clin. Oncol. 22:2602-2609; 2004.
5. Kubota, K.; Watanabe, K.; Kunitoh, H.; Noda, K.; Ichinose, Y.; Katakami, N.; Sugiura, T.; Kawahara, M.; Yokoyama, A.; Yokota, S.; Yoneda, S.; Matsui, K.; Kudo, S.; Shibuya, M.; Isobe, T.; Segawa, Y.; Nishiwaki, Y.; Ohashi, Y.; Niitani, H.; Japanese Taxotere Lung Cancer Study Group. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: The Japanese Taxotere Lung Cancer Study Group. J. Clin. Oncol. 22:254-261; 2004.
6. Yamamoto, N.; Fukuoka, M.; Negoro, S.; Nakagawa, K.; Saito, H.; Matsui, K.; Kawahara, M.; Senba, H.; Takada, Y.; Kudoh, S.; Nakano, T.; Katakami, N.; Sugiura, T.; Hoso, T.; Ariyoshi, Y. Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: A West Japan Thoracic Oncology Group Study (WJTOG9803). Br. J. Cancer 90: 87-92; 2004.
7. Argyriou, A. A.; Polychronopoulos, P.; Iconomou, G.; Koutras, A.; Kalofonos, H. P.; Chroni, E. Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies. J. Neurol. 252:1459-1464; 2005.
8. Belani, C. P.; Ramalingam, S.; Perry, M. C.; LaRocca, R. V.; Rinaldi, D.; Gable, P. S.; Tester, W. J. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J. Clin. Oncol. 26:468-473; 2008.
9. Shukuya, T.; Ishiwata, T.; Hara, M.; Muraki, K.; Shibayama, R.; Koyama, R.; Takahashi, K. Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease. Anticancer Res. 30:4357-4361; 2010.
10. Windebank, A. J.; Grisold, W. Chemotherapy-induced neuropathy. J. Peripher. Nerv. Syst. 13:27-46; 2008.
11. Saltz, L. B.; Clarke, S.; D?az-Rubio, E.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Lichinitser, M.; Yang, T. S.; Rivera, F.; Couture, F.; Sirzén, F.; Cassidy, J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J. Clin. Oncol. 26: 2013-2019; 2008.
12. Johnson, D. H.; Fehrenbacher, L.; Novotny, W. F.; Herbst, R. S.; Nemunaitis, J. J.; Jablons, D. M.; Langer, C. J.; DeVore, 3rd, R. F.; Gaudreault, J.; Damico, L. A.; Holmgren, E.; Kabbinavar, F.; Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22:2184-2191; 2004.
13. Gelderblom, H.; Verweij, J.; Brouwer, E.; Pillay, M.; de, Bruijn, P.; Nooter, K.; Stoter, G.; Sparreboom, A.; Disposition of [G-(3)H] paclitaxel and cremophor EL in a patient with severely impaired renal function. Drug Metab. Dispos. 27:1300-1305; 1999.
14. Rowinsky, E. K.; Gilbert, M. R.; McGuire, W. P.; Noe, D. A.; Grochow, L. B.; Forastiere, A. A.; Ettinger, D. S.; Lubejko, B. G.; Clark, B.; Sartorius, S. E.; Sequences of taxol and cisplatin: A phase I and pharmacologic study. J. Clin. Oncol. 9:1692-1703; 1991.
15. Gauchan, P.; Andoh, T.; Kato, A.; Sasaki, A.; Kuraishi, Y. Effects of the prostaglandin E1 analog limaprost on mechanical allodynia caused by chemotherapeutic agents in mice. J. Pharmacol. Sci. 109:469-472; 2009.
16. Winsor, T.; Simmons, E. M.; Borhani, N.; Hechter, H. H. A diagnostic aid for determining peripheral arteriosclerosis obliterans. Dis. Chest. 52:451-457; 1967.
17. Aboyans, V.; Criqui, M. H.; Denenberg, J. O.; Knoke, J. D.; Ridker, P. M.; Fronek, A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 113:2623-2629; 2006.
18. Argyriou, A. A.; Chroni, E.; Koutras, A.; Iconomou, G.; Papapetropoulos, S.; Polychronopoulos, P.; Kalofonos, H. P. Preventing paclitaxel-induced peripheral neuropathy: A phase II trial of vitamin E supplementation. J. Pain Symptom. Manage. 32:237-244; 2006.
19. Watanabe, T.; Kaji, R.; Oka, N.; Kimura, J. Ultra-high dose methylcobalamin promotes nerve regeneration in experimental acrylamide neuropathy. J. Neurol. Sci. 122: 140-143; 1994.
20. Yamazaki, K.; Oda, K.; Endo, C.; Kikuchi, T.; Wakabayashi, T. Methylcobalamin (methyl-B12) promotes regeneration of motor nerve terminals degenerating in anterior gracile muscle of gracile axonal dystrophy (GAD) mutant mouse. Neurosci. Lett. 28:195-197; 1994.
21. Ahmed, A.; Kothari, M. J. Recovery of neurologic dysfunction with early intervention of vitamin B12. J. Clin. Neuromuscul. Dis. 11:198-202; 2010.
22. Kanbayashi, Y.; Hosokawa, T.; Okamoto, K.; Konishi, H.; Otsuji, E.; Yoshikawa, T.; Takagi, T.; Taniwaki, M. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Anticancer Drugs 21:877-881; 2010.
23. Chen, Y. M.; Perng, R. P.; Shih, J. F.; Tsai, C. M.; Whang-Peng, J. Chemotherapy for non-small cell lung cancer in elderly patients. Chest 128:132-139; 2005.
24. Rao, R. D.; Michalak, J. C.; Sloan, J. A.; Loprinzi, C. L.; Soori, G. S.; Nikcevich, D. A.; Warner, D. O.; Novotny, P.; Kutteh, L. A.; Wong, G. Y.; North Central Cancer Treatment Group. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110:2110-2118; 2007.